William Womack, DO
Family Medicine · Fort Mohave, AZNPI 1679678205
Payments from drug & device makers
Across 143 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$871
- Pfizer$244
- Johnson & Johnson$204
- Lilly USA, LLC$200
- Amgen$179
- AstraZeneca$89
- plus $653 from 17 others
What the payments were for
- Food & beverage$2,435100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 50 | $871 |
| Pfizer | 13 | $244 |
| Johnson & Johnson | 17 | $204 |
| Lilly USA, LLC | 12 | $200 |
| Amgen | 11 | $179 |
| AstraZeneca | 6 | $89 |
| Nevro Corp. | 1 | $86 |
| GSK | 5 | $81 |
| Bayer | 4 | $76 |
| Dexcom, Inc. | 3 | $51 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Sunovion Pharmaceuticals Inc. | 2 | $37 |
| Exact Sciences | 2 | $37 |
| Boehringer Ingelheim | 2 | $37 |
| Viatris Specialty LLC | 1 | $33 |
| Amarin Pharma, Inc. | 2 | $32 |
| Novartis | 2 | $31 |
| Astellas Pharma US Inc | 2 | $30 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Verona Pharma, Inc. | 1 | $16 |
| Merck | 1 | $13 |
| AbbVie | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$2,440 in reported general payments places this provider in the 80th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 205 | $287,370 |
| EliquisApixaban | 156 | $204,413 |
| JardianceEmpagliflozin | 84 | $114,394 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 81 | $107,196 |
| TrulicityDulaglutide | 30 | $58,475 |
| XareltoRivaroxaban | 35 | $37,026 |
| MyrbetriqMirabegron | 23 | $32,322 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 34 | $29,249 |
| FarxigaDapagliflozin Propanediol | 17 | $27,816 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $27,302 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $25,532 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $24,887 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $21,132 |
| TradjentaLinagliptin | 13 | $19,853 |
| JanuviaSitagliptin Phosphate | 12 | $19,507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $871 | $287,370205 claims |
| PfizerEliquis | $244 | $204,413156 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta, Spiriva Respimat, Combivent Respimat | $37 | $187,720156 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $81 | $153,860128 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $200 | $73,41241 claims |
| AstraZenecaFarxiga, Symbicort | $89 | $40,29538 claims |
| Johnson & JohnsonXarelto | $204 | $37,02635 claims |
| Astellas Pharma US IncMyrbetriq | $30 | $32,32223 claims |
| MerckJanuvia | $13 | $19,50712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Fort Mohave
- Danielle ArmasScottsdale$73M
- Terry O'ReillyMesa$35.8M
- Shawn SearleChandler$27M
- Corey AndersonMesa$21.5M
- Dena PetersenTucson$14.7M
- Gerald ShockeyMesa$12.3M
- Brock MerrittPhoenix$8.4M
- John McGettiganTucson$8.3M
- Neil ShethChandler$6.7M
- Joseph LilloScottsdale$6.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.